Cyclodextrin Application and Nanotechnology-based Delivery Systems Research Unit
March 1, 2025 2025-03-01 19:01Cyclodextrin Application and Nanotechnology-based Delivery Systems Research Unit
Cyclodextrin Application and Nanotechnology-based Delivery Systems Research Unit is an expert research unit in the development and application of cyclodextrin and nanotechnology delivery systems. The unit specializes in researching and developing formulations that address various drawback issues. Additionally, this involves exploring and innovating new platforms to enhance the efficiency of drug, as well as conducting research and development for new herbal and cosmetic products. This aims to provide non-invasive alternatives for drug product administration to improve patient compliance. The expertise developed by this research unit has a broad impact on various sectors of the industry, ranging from the design of research and development and the application of cyclodextrin technology, to the use of new nanoparticle delivery platforms. This includes the assessment and control of the manufacturing processes of nanotechnology delivery systems. Additionally, the research unit actively supports and promotes the changes in nanotechnology, contributing to sustainable development in both industry and society in the present and future.
Research & Innovation Focus
Health and Well-Being + Health
Health and Well-Being + Food & Agriculture
Food & Agriculture + Health
Strategic Objectives
Objective 1: Integration of Cyclodextrin-based and Nanotechnology platforms for Sustainable Herbal, Drug and Cosmetic Formulations (SDG 3, 12):
- Develop nanoparticulate systems for herbal, drug, cosmetic delivery, enhancing bioavailability and therapeutic efficacy.
- Evaluate the environmental impact of nanomaterials used in formulations, ensuring compliance with SDG 12 (Responsible Consumption and Production).
- Conduct pre-clinical trials to validate the safety and effectiveness of nanotechnology-enabled herbal, drug, and cosmetics in alignment with SDG 3 (Good Health and Well-being).
- Collaborate with stakeholders to establish protocols and agreements for sustainable production and use of nanotechnology in herbal, drug, and cosmetics.
Objective 2: Empowering Local Communities through Herbal and Cosmetics (SDG 8, 12):
- Develop nano-based cosmetic formulations using locally sourced herbal ingredients, promoting economic growth (SDG 8).
- Implement green manufacturing processes and packaging for herbal and cosmetics to minimize environmental impact (SDG 12).
Objective 3: Accessibility and Affordability of Nanotechnology-Enhanced Herbal, Drug and Cosmetics (SDG 1, 3):
- Develop cost-effective nanotechnology strategies to enhance the accessibility and affordability of herbal, drug, and cosmetics, contributing to SDG 1 (No Poverty).
- Establish partnerships with healthcare providers to integrate nanotechnology-enhanced herbal cosmetics into healthcare practices, supporting SDG 3 (Good Health and Well-being).
These objectives align with translational research goals by emphasizing practical applications of cyclodextrin-based nanotechnology while contributing to SDGs related to promote health, environmental responsibility, innovation, responsible production, poverty reduction, and reduced inequalities.
Target in 3 Years
- Provide knowledge and research regarding the application of cyclodextrin and nanotechnology platforms, such as nanoemulsions, lipid nanoparticles, liposomes, niosomes, and silica nanoparticles, for drug, herbal products, and cosmetic delivery. The research outcomes should be published in international journals listed in the Scopus database, with a minimum of 4 research articles per year.
- Collaborate in research and development for the application of cyclodextrin and nanotechnology delivery systems with at least 1 government agency, state enterprise, or private company. This collaboration aims to gain knowledge for the development of startup businesses or the development of commercial products within a 5-year.
- Engage in academic collaboration with international research organizations to transfer technology. Researchers from the collaborating institution should participate in short-term research internships or student exchange programs related to research within your organization, with at least 1 person per year for 3 years.
Research Highlights
- Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations
- Development of in situ gel containing asiaticoside/cyclodextrin complexes. Evaluation in culture human periodontal ligament cells (HPLDCs)
- Development of celecoxib eye drop solution and microsuspension: A comparative investigation of binary and ternary cyclodextrin complexes
Networks and Partnerships
- Faculty of Pharmaceutical Sciences, University of Iceland
- Faculty of Medicine, University of Iceland
- Faculty of Medicine, NTNU, Trondheim, Norway
- Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
- Chula-Cornell Global Strategic Collaboration, Department of Microbiology, College of Veterinary Medicine, Cornell University, New York, USA
- Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, USA
- BIOTEC, NSTDA, Thailand
